KBC Group NV Has $91,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

KBC Group NV boosted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 105.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,303 shares of the biotechnology company’s stock after buying an additional 6,321 shares during the period. KBC Group NV’s holdings in Iovance Biotherapeutics were worth $91,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of IOVA. Handelsbanken Fonder AB lifted its holdings in Iovance Biotherapeutics by 18.2% in the third quarter. Handelsbanken Fonder AB now owns 74,800 shares of the biotechnology company’s stock valued at $702,000 after buying an additional 11,500 shares during the period. Brookstone Capital Management increased its stake in Iovance Biotherapeutics by 43.9% in the third quarter. Brookstone Capital Management now owns 20,055 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 6,120 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Iovance Biotherapeutics by 11.6% in the third quarter. Exchange Traded Concepts LLC now owns 17,071 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 1,776 shares in the last quarter. Shaker Investments LLC OH increased its stake in Iovance Biotherapeutics by 27.7% in the third quarter. Shaker Investments LLC OH now owns 100,712 shares of the biotechnology company’s stock valued at $946,000 after purchasing an additional 21,859 shares in the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in Iovance Biotherapeutics in the third quarter valued at $89,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock opened at $5.69 on Monday. Iovance Biotherapeutics, Inc. has a 52-week low of $5.52 and a 52-week high of $18.33. The company has a 50-day simple moving average of $7.06 and a two-hundred day simple moving average of $8.92. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -3.82 and a beta of 0.53.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The business had revenue of $58.56 million during the quarter, compared to the consensus estimate of $53.54 million. During the same period in the prior year, the firm posted ($0.46) EPS. On average, sell-side analysts forecast that Iovance Biotherapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IOVA shares. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Wednesday, November 6th. UBS Group assumed coverage on shares of Iovance Biotherapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $17.00 target price for the company. Finally, Piper Sandler decreased their target price on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating for the company in a research report on Friday, January 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.69.

Insiders Place Their Bets

In other Iovance Biotherapeutics news, Director Ryan D. Maynard sold 50,000 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total value of $503,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $75,450. This represents a 86.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 12.10% of the stock is currently owned by insiders.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.